News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

PsiOxus Therapeutics Limited Initiates "OCTAVE" Ovarian Cancer Study For Oncolytic Vaccine Enadenotucirev


6/17/2014 11:24:18 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

OXFORD, England--(BUSINESS WIRE)--PsiOxus Therapeutics Ltd. (PsiOxus), an award-winning biotechnology company developing innovative new treatments for cancer, today announced the first dosing of a patient in the OCTAVE (Ovarian Cancer Treated with Adeno Vaccine Enadenotucirev) study. OCTAVE is a phase I/II clinical trial to assess the safety and efficacy of its oncolytic vaccine enadenotucirev (previously known as ColoAd1) in platinum-resistant ovarian cancer patients at multiple UK cancer centres beginning this month. Enadenotucirev has shown potent, broad-spectrum, anti-cancer activity pre-clinically and is also in phase I/II clinical trials in patients with colorectal tumours.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES